223 related articles for article (PubMed ID: 34856888)
1. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Mason NJ; Chester N; Xiong A; Rotolo A; Wu Y; Yoshimoto S; Glassman P; Gulendran G; Siegel DL
MAbs; 2021; 13(1):2004638. PubMed ID: 34856888
[TBL] [Abstract][Full Text] [Related]
2. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
Marable J; Ruiz D; Jaiswal AK; Bhattacharya R; Pantazes R; Agarwal P; Suryawanshi AS; Bedi D; Mishra A; Smith BF; Sandey M
Sci Rep; 2021 Oct; 11(1):20763. PubMed ID: 34675296
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.
Davis-Marcisak EF; Fitzgerald AA; Kessler MD; Danilova L; Jaffee EM; Zaidi N; Weiner LM; Fertig EJ
Genome Med; 2021 Aug; 13(1):129. PubMed ID: 34376232
[TBL] [Abstract][Full Text] [Related]
7. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
8. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
9. Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.
Haran KP; Lockhart A; Xiong A; Radaelli E; Savickas PJ; Posey A; Mason NJ
Vet Pathol; 2020 Mar; 57(2):241-252. PubMed ID: 32081102
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
11. Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig.
Graves SS; Stone D; Loretz C; Peterson L; McCune JS; Mielcarek M; Storb R
Transplantation; 2009 Aug; 88(3):317-22. PubMed ID: 19667932
[TBL] [Abstract][Full Text] [Related]
12. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
14. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade.
Naidoo J; Page DB; Wolchok JD
Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
[TBL] [Abstract][Full Text] [Related]
16. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.
Persson J; Beyer I; Yumul R; Li Z; Kiem HP; Roffler S; Lieber A
PLoS One; 2011; 6(7):e22303. PubMed ID: 21779410
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
Camacho LH
Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
[TBL] [Abstract][Full Text] [Related]
18. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
19. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
